Wixela Inhub (fluticasone propionate and salmeterol inhalation powder) was approved by the US FDA in January 2019, for the treatment of patients with asthma or chronic obstructive pulmonary disease (COPD).
The list prices for Wiexla Inhub 100mcg/50mcg, 250mcg/50mcg, 500mcg/50mcg will be offered at $93.71, $116.44 and $153.14, respectively.
Mylan’s chief commercial officer Tony Maura said in a statement that Mylan believes that the launch of Wiexla Inhub at a discounted list price will demonstrate the savings that generics can deliver for patients – reducing out-of-pocket costs and providing savings to the US health care system.
GlaxoSmithKline previously had the only generic on the market for this product, with its own version of its branded product. The company saw an extension to this non-competition period after Mylan received a complete response letter (CRL) in June 2018; however, Mylan’s Wixela Inhub is now on the market at a third of the cost of GSK’s product.
Mylan’s recently approval saw its shares rise by 7% immediately.